Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 7/20 | 0.46 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21582896 | 0.89 | EPHX1 (0.58) | EPHX1EPHX2KDM4CKDM4EMEN1 | |
| SCHEMBL6280293 | 0.89 | EPHX1 (0.44) | EPHX1PRMT1EPHX2USP2TSHR | |
| SCHEMBL4545267 | 0.88 | — | — | |
| Hydrochloric Acid SCHEMBL23834081 | 0.87 | EPHX1 (0.43) | EPHX1PRMT1EPHX2USP2TSHR | |
| SCHEMBL6290325 | 0.85 | EPHX1 (0.68) | EPHX1EPHX2 | |
| SCHEMBL20879978 | 0.85 | EPHX1 (0.37) | EPHX1PRMT1EPHX2KDM4EMAPK1 | |
| SCHEMBL15984870 | 0.85 | EPHX1 (0.37) | EPHX1PRMT1EPHX2MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL23834079 | 0.85 | EPHX1 (0.41) | EPHX1EPHX2USP2TSHRKDM4C | |
| SCHEMBL11231320 | 0.82 | EPHX1 (0.54) | EPHX1PRMT1EPHX2KEAP1NFE2L2 | |
| SCHEMBL19172568 | 0.81 | KEAP1 (0.47) | EPHX1PRMT1EPHX2USP2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024052692-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2024-03-14 | — | — | WO | disclosed |
| CN-108929705-B | Liquid crystal aligning agent, liquid crystal alignment film, method for producing same, liquid crystal element, polymer, and diamine | JSR株式会社 | 2023-05-30 | — | — | CN | disclosed |
| EP-3122328-B1 | SILANE CONTAINING RESPECTIVELY AT LEAST TWO ALKOXY GROUPS AND A GUANIDONO OR CARBAMIDE GROUP | EVONIK DEGUSSA GMBH (DE) | 2019-05-01 | — | — | EP | disclosed |
| WO-2015144384-A1 | SILANE CONTAINING RESPECTIVELY AT LEAST TWO ALKOXY GROUPS AND A GUANIDONO OR CARBAMIDE GROUP | EVONIK DEGUSSA GMBH (DE) | 2015-10-01 | — | — | WO | disclosed |
| US-20140243322-A1 | BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME | COFERON, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| WO-2013033268-A2 | BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME | COFERON, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243322-A1 | BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME | BRDT, BRD2, BRD4 | EPHX1 3677/4885PRMT1 1082/4885EPHX2 1893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.